Seeking Alpha

Alkermes (ALKS) says top-line results from a phase 2b dose-ranging clinical study of ALKS 37 in...

Alkermes (ALKS) says top-line results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation did not satisfy its pre-specified criteria for advancing into phase 3 clinical trials. Based on the evaluation, Alkermes has decided not to advance ALKS 37 and will consider out-licensing opportunities.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|